The shuttering of Teva’s long troubled manufacturing facility in Irvine, California, may create shortages of up to 24 generic sterile injectable drugs, including five essential medications of which the company supplied more than 15% of the market last year, according to an industry group.
Enforcement Report - Week of August 25, 2021
Enforcement Report - Week of March 3, 2021
Sun Pharm`s Generic Epoprostenol Sodium Receives Tentative Approval In US
J&J unit to pay $360 million to U.S. to resolve charity kickback probe
FDA Confirms Paragraph IV Patent Challenge of Veletri (Epoprostenol Sodium) Injection
Drug Recall: Flolan (2015-03-20)
United Therapeutics Announces Signing of Agreement for New Remodulin Delivery System